Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1378–1384. doi: 10.1038/sj.bjc.6694223

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

A Garaventa 1, O Bellagamba 1, M S Lo Piccolo 1, C Milanaccio 1, E Lanino 1, L Bertolazzi 2, G P Villavecchia 2, M Cabria 2, G Scopinaro 2, F Claudiani 2, B De Bernardi 1
PMCID: PMC2362971  PMID: 10604736

Abstract

Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4) Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22–153 months (median, 59) from diagnosis. 131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe. © 1999 Cancer Research Campaign

Keywords: neuroblastoma, radiometabolic therapy, 131I-metaiodobenzylguanidine

Full Text

The Full Text of this article is available as a PDF (95.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beierwaltes W. H. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives. Med Pediatr Oncol. 1987;15(4):188–191. doi: 10.1002/mpo.2950150409. [DOI] [PubMed] [Google Scholar]
  2. Bolster A. A., Hilditch T. E., Wheldon T. E., Gaze M. N., Barrett A. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children. Br J Radiol. 1995 May;68(809):481–490. doi: 10.1259/0007-1285-68-809-481. [DOI] [PubMed] [Google Scholar]
  3. Brodeur G. M., Pritchard J., Berthold F., Carlsen N. L., Castel V., Castelberry R. P., De Bernardi B., Evans A. E., Favrot M., Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. doi: 10.1200/JCO.1993.11.8.1466. [DOI] [PubMed] [Google Scholar]
  4. Buck J., Bruchelt G., Girgert R., Treuner J., Niethammer D. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res. 1985 Dec;45(12 Pt 1):6366–6370. [PubMed] [Google Scholar]
  5. Castleberry R. P., Kun L. E., Shuster J. J., Altshuler G., Smith I. E., Nitschke R., Wharam M., McWilliams N., Joshi V., Hayes F. A. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol. 1991 May;9(5):789–795. doi: 10.1200/JCO.1991.9.5.789. [DOI] [PubMed] [Google Scholar]
  6. De Bernardi B., Carli M., Casale F., Corciulo P., Cordero di Montezemolo L., De Laurentis C., Bagnulo S., Brisigotti M., Marchese N., Garaventa A. Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1992 Dec;10(12):1870–1878. doi: 10.1200/JCO.1992.10.12.1870. [DOI] [PubMed] [Google Scholar]
  7. Flower M. A., Fielding S. L. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma. Phys Med Biol. 1996 Oct;41(10):1933–1940. doi: 10.1088/0031-9155/41/10/006. [DOI] [PubMed] [Google Scholar]
  8. Garaventa A., De Bernardi B., Pianca C., Donfrancesco A., Cordero di Montezemolo L., Di Tullio M. T., Bagnulo S., Mancini A., Carli M., Pession A. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1993 Sep;11(9):1770–1779. doi: 10.1200/JCO.1993.11.9.1770. [DOI] [PubMed] [Google Scholar]
  9. Garaventa A., Guerra P., Arrighini A., Bertolazzi L., Bestagno M., De Bernardi B., Lanino E., Villavecchia G. P., Claudiani F. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer. 1991 Feb 15;67(4):922–928. doi: 10.1002/1097-0142(19910215)67:4<922::aid-cncr2820670411>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  10. Gaze M. N., Wheldon T. E., O'Donoghue J. A., Hilditch T. E., McNee S. G., Simpson E., Barrett A. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer. 1995;31A(2):252–256. doi: 10.1016/0959-8049(94)e0036-4. [DOI] [PubMed] [Google Scholar]
  11. Geatti O., Shapiro B., Sisson J. C., Hutchinson R. J., Mallette S., Eyre P., Beierwaltes W. H. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med. 1985 Jul;26(7):736–742. [PubMed] [Google Scholar]
  12. Haase G. M., Atkinson J. B., Stram D. O., Lukens J. N., Matthay K. K. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg. 1995 Feb;30(2):289–295. doi: 10.1016/0022-3468(95)90576-6. [DOI] [PubMed] [Google Scholar]
  13. Jaques S., Jr, Tobes M. C., Sisson J. C. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 1987 Aug 1;47(15):3920–3928. [PubMed] [Google Scholar]
  14. Klingebiel T., Treuner J., Ehninger G., Keller K. D., Dopfer R., Feine U., Niethammer D. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol. 1989;25(2):143–148. doi: 10.1007/BF00692356. [DOI] [PubMed] [Google Scholar]
  15. Lashford L. S., Lewis I. J., Fielding S. L., Flower M. A., Meller S., Kemshead J. T., Ackery D. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992 Dec;10(12):1889–1896. doi: 10.1200/JCO.1992.10.12.1889. [DOI] [PubMed] [Google Scholar]
  16. Leavey P. J., Odom L. F., Poole M., McNeely L., Tyson R. W., Haase G. M. Intra-operative radiation therapy in pediatric neuroblastoma. Med Pediatr Oncol. 1997 Jun;28(6):424–428. doi: 10.1002/(sici)1096-911x(199706)28:6<424::aid-mpo6>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  17. Mastrangelo R., Lasorella A., Iavarone A., Rufini V., Troncone L., Danza F., Riccardi R. Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis. Med Pediatr Oncol. 1993;21(6):411–415. doi: 10.1002/mpo.2950210604. [DOI] [PubMed] [Google Scholar]
  18. Mastrangelo R., Tornesello A., Mastrangelo S. Role of 131I-metaiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol. 1998 Jul;31(1):22–26. doi: 10.1002/(sici)1096-911x(199807)31:1<22::aid-mpo5>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  19. Matthay K. K., DeSantes K., Hasegawa B., Huberty J., Hattner R. S., Ablin A., Reynolds C. P., Seeger R. C., Weinberg V. K., Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998 Jan;16(1):229–236. doi: 10.1200/JCO.1998.16.1.229. [DOI] [PubMed] [Google Scholar]
  20. Montaldo P. G., Lanciotti M., Casalaro A., Cornaglia-Ferraris P., Ponzoni M. Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res. 1991 Aug 15;51(16):4342–4346. [PubMed] [Google Scholar]
  21. Philip T., Ladenstein R., Lasset C., Hartmann O., Zucker J. M., Pinkerton R., Pearson A. D., Klingebiel T., Garaventa A., Kremens B. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer. 1997 Oct;33(12):2130–2135. doi: 10.1016/s0959-8049(97)00324-9. [DOI] [PubMed] [Google Scholar]
  22. Powis M. R., Imeson J. D., Holmes S. J. The effect of complete excision on stage III neuroblastoma: a report of the European Neuroblastoma Study Group. J Pediatr Surg. 1996 Apr;31(4):516–519. doi: 10.1016/s0022-3468(96)90486-8. [DOI] [PubMed] [Google Scholar]
  23. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Nelp W. B., Glenn S., Fisher D. R., Porter B., Matthews D. C., Gooley T. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995 Aug 5;346(8971):336–340. doi: 10.1016/s0140-6736(95)92225-3. [DOI] [PubMed] [Google Scholar]
  24. Schwabe D., Sahm S., Gerein V., Happ J., Kropp-von Rabenau H., Maul F., Baum R. P., Manegold K., Nitz C., Hör G. 131-Metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experience. Eur J Pediatr. 1987 May;146(3):246–250. doi: 10.1007/BF00716467. [DOI] [PubMed] [Google Scholar]
  25. Sisson J. C., Shapiro B., Hutchinson R. J., Shulkin B. L., Zempel S. Survival of patients with neuroblastoma treated with 125-I MIBG. Am J Clin Oncol. 1996 Apr;19(2):144–148. doi: 10.1097/00000421-199604000-00011. [DOI] [PubMed] [Google Scholar]
  26. Weber W., Weber J., Senekowitsch-Schmidtke R. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Res. 1996 Dec 1;56(23):5428–5434. [PubMed] [Google Scholar]
  27. van Hasselt E. J., Heij H. A., de Kraker J., Vos A., Voûte P. A. Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma. Eur J Pediatr Surg. 1996 Jun;6(3):155–158. doi: 10.1055/s-2008-1066495. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES